Total Valuation
Dermapharm Holding SE has a market cap or net worth of CHF1.86B. The enterprise value is CHF3.31K.
Market CapCHF1.86B
Enterprise ValueCHF3.31K
Share Statistics
Dermapharm Holding SE has 49,540,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,540,810
Owned by Insiders89.83%
Owned by Institutions―
Financial Efficiency
Dermapharm Holding SE’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 7.97%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.97%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee332.57K
Profits Per Employee37.80K
Employee Count3,503
Asset Turnover0.53
Inventory Turnover2.35
Valuation Ratios
The current PE Ratio of Dermapharm Holding SE is 14.3. Dermapharm Holding SE’s PEG ratio is 0.96.
PE Ratio14.3
PS Ratio1.82
PB Ratio3.05
Price to Fair Value3.05
Price to FCF15.20
Price to Operating Cash Flow8.91
PEG Ratio0.96
Income Statement
In the last 12 months, Dermapharm Holding SE had revenue of 1.16B and earned 132.41M in profits. Earnings per share was 2.46.
Revenue1.16B
Gross Profit391.71M
Operating Income221.75M
Pretax Income183.51M
Net Income132.41M
EBITDA314.31M
Earnings Per Share (EPS)2.46
Cash Flow
In the last 12 months, operating cash flow was 219.81M and capital expenditures -48.39M, giving a free cash flow of 171.43M billion.
Operating Cash Flow219.81M
Free Cash Flow171.43M
Free Cash Flow per Share3.46
Dividends & Yields
Dermapharm Holding SE pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Dermapharm Holding SE upcoming earnings date is Nov 12, 2026, TBA (Confirmed).
Last Earnings DateAug 25, 2026
Next Earnings DateNov 12, 2026
Ex-Dividend Date―
Financial Position
Dermapharm Holding SE as a current ratio of 2.05, with Debt / Equity ratio of 29.14%
Current Ratio2.05
Quick Ratio1.09
Debt to Market Cap0.48
Net Debt to EBITDA2.70
Interest Coverage Ratio4.21
Taxes
In the past 12 months, Dermapharm Holding SE has paid 52.16M in taxes.
Income Tax52.16M
Effective Tax Rate0.28
Enterprise Valuation
Dermapharm Holding SE EV to EBITDA ratio is 9.44, with an EV/FCF ratio of 21.29.
EV to Sales2.55
EV to EBITDA9.44
EV to Free Cash Flow21.29
EV to Operating Cash Flow16.35
Balance Sheet
Dermapharm Holding SE has CHF195.56M in cash and marketable securities with CHF156.40M in debt, giving a net cash position of CHF39.17M billion.
Cash & Marketable SecuritiesCHF195.56M
Total DebtCHF156.40M
Net CashCHF39.17M
Net Cash Per ShareCHF0.79
Tangible Book Value Per Share-CHF6.79
Margins
Gross margin is 34.73%, with operating margin of 19.03%, and net profit margin of 11.37%.
Gross Margin34.73%
Operating Margin19.03%
Pretax Margin15.75%
Net Profit Margin11.37%
EBITDA Margin26.98%
EBIT Margin19.03%
Analyst Forecast
The average price target for Dermapharm Holding SE is CHF48.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF48.83
Price Target Upside― Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-1.50%
EPS Growth Forecast35.85%